Oculis Holding AG Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Oculis Holding AG (NASDAQ: OCS) or certain of its executive officers violated federal securities laws. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.
What if I purchased Oculis securities?
If you purchased Oculis securities and suffered losses on your investment, join our investigation now: Click Here to Join the Investigation.
Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.
There is no cost or obligation to you.
Background of the Investigation
On April 20, 2026, Oculis announced that the last patient visits for both Phase 3 DIAMOND trials had been completed and that topline results were expected in June 2026. The Company stated that, if the results were positive, it expected to prepare for a planned New Drug Application submission to the FDA later in 2026.
On May 11, 2026, Oculis reported its first quarter 2026 financial results and stated that its pipeline was “advancing as planned,” that the DIAMOND data readout remained on track, and that the Company had begun 2026 with “strong execution momentum across our late-stage clinical trials.”
Then, on May 29, 2026, Oculis announced topline results from the Phase 3 DIAMOND-1 and DIAMOND-2 trials. The Company disclosed that both trials failed to meet the primary endpoint of mean change in BCVA at Week 52 and also failed to meet the key secondary endpoint measuring the proportion of patients with a gain of at least 15 letters in BCVA. Although Oculis reported substantial and sustained reductions in retinal thickness, the Company stated that those reductions did not translate into BCVA improvement at Week 52. Oculis further disclosed that, based on the results, it did not plan to pursue an FDA regulatory filing for OCS-01 in DME at that time.
Following this disclosure, Oculis’s stock price declined sharply.
In light of this disclosure, Johnson Fistel is investigating whether Oculis complied with state and federal laws, including the federal securities laws. If you suffered losses, or are a long-term holder of Oculis stock, contact Johnson Fistel.
About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder class actions and derivative lawsuits. Johnson Fistel has been recognized as one of the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. In 2024, the firm recovered approximately $90,725,000 for investors.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | jimb@johnsonfistel.com | fjohnson@johnsonfistel.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
